Suppl. Fig.1Matsuyama

c

Bax (1g)+Ku80

0

20

40

60

80

Contro

l

Ku80+Vect

or0.5

g1.0

g2.0

g

Bax+Vect

or

Apo

ptos

is (%

)

Ku80

-Tubulin

Contro

l

Ku80

Ku70

-Tubulin

Ku80

Contro

l 0.

5g

1.0

g 2.

0g

Ku70wtb

a

Bax+Ku70

100 101 102 103 104FL2-H

M1

15.25%

020

0C

ount

s

Bax+z-VAD

100 101 102 103 104FL2-H

M1

020

0C

ount

s

16.49%

No PI

Contro

l

Bax Bax+Ku70

Bax+z-V

AD

020

0C

ount

s

Control

100 101 102 103 104FL2-H

M1

8.78%Bax

100 101 102 103 104FL2-H

M1

43.75%

020

0C

ount

s

020

0C

ount

sNo PI

100 101 102 103 104FL2-H

M1

0%

1. NRS2. Anti-Bax3. Mouse IgG4. Anti-Ku705. Molecular Marker6. NRS7. Anti-Bax8. Mouse IgG9. Anti-Ku70

Input

IP

IP

4131

187

1 2 3 4 5 6 720012785

Ku70

a

NS

NS

4131

187

1 2 3 4 5 6 720012785

Ku70

c

NS

NS

1 2 3 4 5 8 9

17

202121

31

79

41

8

Bax

NSNS

d

b

Bax

1 2 3 4 5 8 9200127854131

18

7

Suppl. Fig.2Matsuyama

1. NRS2. Anti-Ku703. Mouse IgG4. Anti-Bax5. Molecular Marker6. Mouse IgG7. Anti-Bax8. NRS9. Anti-Ku70

Input

IP

IP

200127 85 41 31

18 7

1 2 3 4 5 8 9

Bax

b200127 85

41 31

18 7

1 2 3 4 5 6 7

Ku70

a

NS

c200127 85

41 31

18 7

1 2 3 4 5 6 7

Ku70

NS

NS

NS

d200127 85 41 31 18 7

1 2 3 4 5 8 9

Bax

NS NS

Suppl. Fig.3Matsuyama

NRS A

nti-Ku70

Anti-

Bax

NRSAnti-

Ku70

Anti-

Bax

Input

Input

IP

Ku70 Ku70

Ku70

Bax

Bax

Bax

CytosolNRS

Anti-

Ku70

Anti-

Bax

NRS A

nti-Ku70

Anti-

Bax

Input

Input

IP

Ku70 Ku70

Ku70

Bax

Bax

Bax

Total

e

a- + - + - + - +z-VAD

- -+ +- +

STSAlkali

Bax

F1

Suppl. Fig.4

74k

32k

GFP

GFP-Bax

wt

GFP-B

ax N

GFP-Bax

P13A

Input (GFP-Bax)

Input(Ku70)

IP

Ku70

Ku70

cb

0

10

20

30

40

50

Contro

lBax

+Vector

Bax+Ku70

Bax P13

A+Vect

orBax

P13A

+Ku70

Apo

ptos

is (%

)d

-Tubulin

0 3 6 12 24UV treatment time (h)

85

4131

187

200127

Ku70

fNo t

reatm

ent

UV No trea

tmen

t

UV+z-VAD

STSSTS+z-V

AD

116kDa

85kDa

-Tubulin

PARP

Matsuyama

Control

STSSTS+z-V

AD

85

4131

187

200127

Ku70

e